CC Sees Gains From Opteon Growth in Q2, Navigates Disruptions in TT

Key Takeaways CC expects Q2 adjusted EBITDA of $215-$225M and positive free cash flow for the quarter. TSS projects 25% sales and 40% EBITDA growth from strong Opteon demand under the AIM Act. TT sees a 15% EBITDA drop from $15M higher costs in disruptions; APM EBITDA to rise 25% on cost strength.The Chemours Company (CC) updated its second-quarter 2025 outlook ending June 30. CC expects consolidated net sales for the second quarter to be at the high end of the original range, expecting a sequential mid-t ...